Staphylococcus aureus bacteraemia of unknown primary source: Where do we stand?

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 1, 2008, Pages

  Saginur, Raphael ^a   Suh, Kathryn N ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bacteraemia; Complications; Investigations; Management; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFTAZIDIME; CEFTOBIPROLE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; NAFCILLIN; PENICILLIN G; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANAMNESIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BLOOD CULTURE; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL FEATURE; COMMUNITY ACQUIRED INFECTION; DRUG EFFICACY; HEALTHCARE ACQUIRED INFECTION; HEART VALVE BIOPROSTHESIS; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PENICILLIN RESISTANCE; PHENOTYPE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROSTHESIS INFECTION; RADIODIAGNOSIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THORAX RADIOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

BACTEREMIA; CATHETERS, INDWELLING; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ENDOCARDITIS; HUMANS; INCIDENCE; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 53849120901     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.008     Document Type: Article

References (36)

1. Noskin G.A., Rubin R.J., Schentag J.J., Kluytmans J., Hedblom E.C., Smulders M., et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 nationwide inpatient sample database. Arch Intern Med 165 (2005) 1756-1761
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
3. Wilson R., and Hamburger M. Fifteen years' experience with Staphylococcus septicemia in a large city hospital. Am J Med (1957) 437-457
4. Nolan C.M., and Beaty H.N. Staphylococcus aureus bacteremia. Am J Med 60 (1976) 495-500
5. Wyllie D.H., Crook D.W., and Peto T.E.A. Mortality after Staphylococcus aureus bacteraemia in two acute hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 333 (2006) 281 [Erratum. BMJ 2006;333:468].
6. Johnson A.P., Pearson A., and Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother 56 (2005) 455-462
7. Kaech C., Elzi L., Sendi P., Frei R., Laifer G., Bassetti S., et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary centre. Clin Microbiol Infect 12 (2006) 345-352
8. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666-674
9. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 (2002) 53-59
10. Whitby M., McLaws M.L., and Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 175 (2001) 264-267
11. Chang F.Y., MacDonald B.B., Peacock Jr. J.E., Musher D.M., Triplett P., Mylotte J.M., et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82 (2003) 322-332
12. Shurland S., Zhan M., Bradham D.D., and Roghmann M.-C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28 (2007) 273-279
13. Wang J.L., Chen S.Y., Wang J.T., Wu G.H.M., Chiang W.C., Hsueh P.R., et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis 46 (2008) 799-806
14. Popovich K.J., Weinstein R.A., and Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis 46 (2008) 787-794
15. Gonzales B.E., Rueda A.M., Shelburne III S.A., Musher D.M., Hamill R.J., and Hulten K.G. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 27 (2006) 1051-1056
16. DeFrances C.J., and Hall M.J. 2005 National Hospital Discharge Survey. Adv Data 385 (2007) 1-19
17. Vongpatanasin W., Hillis L.D., and Lange R.A. Prosthetic heart valves. N Engl J Med 335 (1996) 407-416
18. Chu V.H., Crosslin D.R., Friedman J.Y., Reed S.D., Cabel C.H., Griffiths R.I., et al. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med 118 (2005) 19-24
19. Murdoch D.R., Roberts S.A., Fowler V.G., Shah M.N., Taylor S.L., Morris A.J., et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 32 (2001) 647-649
20. El-Ahdab F., Benjamin D.K., Wang A., Cabell C.H., Chu V.H., Stryjewski M.E., et al. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med 118 (2005) 225-229
21. Khatib R., Riederer K., Saeed S., Johnson L.B., Fakih M.G., Sharma M., et al. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with source and outcome of infection. Clin Infect Dis 41 (2005) 594-598
22. Marra A.R., Edmond M.B., Forbes B.A., Wenzel R.P., and Bearman G.M.L. Time to culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 44 (2006) 1342-1346
23. Hawkins C., Huang J., Jin N., Noskin G.A., Zembower T.R., and Bolon M. Persistent Staphylococcus aureus bacteremia. Arch Intern Med 167 (2007) 1861-1867
24. Khatib R., Johnson L.B., Fakih M.G., Riederer K., Khosrovaneh A., Tabriz M.S., et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 38 (2006) 7-14
25. Fowler V.G., Li J., Corey G.R., Boley J., Marr K.A., Gopal A.K., et al. Role of echocardiography in evaluation of patients with Staphylococcus bacteremia: experience in 103 patients. J Am Coll Cardiol 30 (1997) 1072-1078
26. Rosen A.B., Fowler V.G., Corey G.R., Downs S.M., Bibble A.K., Li J., et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 130 (1999) 810-820
27. Van Hal S.J., Mathur G., Kelly J., Aronis C., Cranney G.B., and Jones P.D. The role of transthoracic echocardiography in excluding left sided infective endocarditis in Staphylococcus aureus bacteraemia. J Infect 51 (2005) 218-221
28. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 51 RR-10 (2002) 1-29
29. Ekkelenkamp M.B., van der Bruggen T., van de Vijver D.A.M.C., Wolfs T.F.W., and Bonten M.J.M. Bacteremic complications of intravascular catheters colonized with Staphylococcus aureus. Clin Infect Dis 46 (2008) 114-118
30. Mohr J.F., and Murray B.E. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44 (2007) 1536-1542
31. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 44 (2007) 1543-1548
32. Reinert R.R., Low D.E., Rosi F., Zhang X., Wattal C., and Dowzicky M.J. Antimicrobial susceptibility among organisms collected from the Asia/Pacific Rim. Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007) 1018-1029
33. Sievert D.M., Rudrik J.T., Patel J.B., McDonald L.C., Wilkins M.J., and Hageman J.C. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46 (2008) 668-674
34. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
35. Fowler Jr. V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin vs. standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
36. Noel G.J., Bush K., Bagchi P., Ianus J., and Strauss R.S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46 (2008) 647-655